Brilinta Taiwan Post Approval Safety Study

NCT02406248 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Non ST-elevation Myocardial Infarction

Interventions

DRUG: Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)

Sponsor

AstraZeneca